Toxic and drug-induced myopathies

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 80, Issue 8, 2009, Pages 832-838

  Dalakas, M C ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMINOCAPROIC ACID; AMIODARONE; ATORVASTATIN; CERIVASTATIN; CHLOROQUINE; COLCHICINE; CORTICOSTEROID; CYCLOSPORIN A; DEXAMETHASONE; DIDANOSINE; EMETINE; FIALURIDINE; FLUINDOSTATIN; GABAPENTIN; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAMIVUDINE; MEVINOLIN; PENICILLAMINE; PRAVASTATIN; PREDNISONE; PREGABALIN; PROCAINAMIDE; RECREATIONAL DRUG; SIMVASTATIN; STAVUDINE; TACROLIMUS; TRYPTOPHAN; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRHEUMATIC AGENT; DRUG;

ALCOHOLISM; ANTIMICROBIAL MYOPATHY; ANTIMICROTUBULE MYOPATHY; ASTHMA; CARDIOTOXICITY; CHRONIC ACTIVE HEPATITIS; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORNEA DYSTROPHY; CORTICOSTEROID INDUCED MYOPATHY; CREATINE KINASE BLOOD LEVEL; DERMATOMYOSITIS; DISEASE ASSOCIATION; DRUG ANTAGONISM; DRUG CONTAMINATION; DRUG DEPENDENCE; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; EOSINOPHILIA MYALGIA SYNDROME; FASCIITIS; GENE INSERTION; GENETIC PREDISPOSITION; HISTOPATHOLOGY; HUMAN; HYPERCHLOREMIA; HYPERKALEMIA; INTOXICATION; LACTIC ACIDOSIS; LYSOSOMAL STORAGE MYOPATHY; MITOCHONDRIAL MYOPATHY; MONOTHERAPY; MUSCLE ATROPHY; MUSCLE BIOPSY; MUSCLE FATIGUE; MUSCLE MITOCHONDRION; MUSCLE WEAKNESS; MUSCULAR DYSTROPHY; MYALGIA; MYASTHENIA; MYASTHENIA GRAVIS; MYOFIBRILLAR MYOPATHY; MYOFIBROSIS; MYOGLOBINURIA; MYOPATHY; MYOSITIS; NECROTISING MYOPATHY; NEOPLASM; NEUROPATHY; NONHUMAN; PARALYSIS; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; POLYMYOSITIS; PRIORITY JOURNAL; RETINA MACULA DEGENERATION; REVIEW; RHABDOMYOLYSIS; SENSORY NEUROPATHY; THICK FILAMENT LOSS MYOPATHY; TOXIC MYOPATHY; TOXIC OIL SYNDROME; TRANSGENE; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; ADDICTION; CHEMICALLY INDUCED DISORDER; DIET SUPPLEMENTATION; INTRAMUSCULAR DRUG ADMINISTRATION; MUSCLE DISEASE; PATHOLOGY;

ANTI-HIV AGENTS; ANTIRHEUMATIC AGENTS; DIETARY SUPPLEMENTS; DRUG CONTAMINATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INJECTIONS, INTRAMUSCULAR; MUSCULAR DISEASES; PHARMACEUTICAL PREPARATIONS; SUBSTANCE-RELATED DISORDERS;

EID: 67849122405     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2008.168294     Document Type: Review

References (40)

1. Sieb JP, Gillessen T. Iatrogenic and toxic myopathies. Muscle Nerve 2003;27:142-56.
2. Dalakas MC. Inflammatory and toxic myopathies. Curr Opin Neurol Neurosurg 1992;5:645-54.
3. Guis S, Mattéi JP, Lioté F. Drug-induced and toxic myopathies. Best Pract Res Clin Rheumatol 2003;17:877-907.
4. Dalakas MC. Diseases of the muscle and neuromuscular junction. Sci Amer® Med. In: Dale DC, Fedderman DD, eds. New York: WebMD, 2003:2155-71.
5. Klopstock T. Drug-induced myopathies. Curr Opin Neurol 2008;21:590-5.
6. Kuncl RW. Colchicine myopathy and neuropathy. New Engl J Med 1987;316:1562-8.
7. Siddiqui AK, Huberfeld SI, Weidenheim KM, et al. Hydroxychloroquine-induced toxic myopathy causing respiratory failure. Chest 2007;131:588-90.
8. Clark LT. Treating dyslipidemia with statins: the risk-benefit profile. Am Heart J 2003;145:387-96.
9. Bolego C, Baetta R, Bellosta S, et al. Safety considerations for statins. Curr Opin Lipidol 2002;13:637-44.
10. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681-90.
11. Baer AN, Wortmann RL. Myotoxicity associated with lipid-lowering drugs. Curr Opin Rheumatol 2007;19:67-73.
12. Waclawik AJ, Lindal S, Engel AG. Experimental lovastatin myopathy. J Neuropathol Exp Neurol 1993;52:542-9.
13. Ghirlanda G, Oradei A, Manto A, et al. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J Clin Pharmacol 1993;33:226-9.
14. Hendrix S, Nitsch R. The role of T helper cells in neuroprotection and regeneration. J Neuroimmunol 2007;184:100-12.
15. Mira E, León B, Barber DF, et al. Statins induce regulatory T cell recruitment via a CCL1 dependent pathway. J Immunol 2008;181:3524-34.
16. Vasconcelos OM, Campbell WW. Dermatomyositis-like syndrome and HMG-CoA reductase inhibitor (statin) intake. Muscle Nerve 2004;30:803-7.
17. Chang JT, Staffa JA, Parks M, et al. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol Drug Saf 2004;13:417-26.
18. Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 2002;36:288-95.
19. Vladutiu GD. Genetic predisposition to statin myopathy. Curr Opin Rheumatol 2008;20:648-55.
20. SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy - a genomewide study. New Engl J Med 2008;359:789-99.
21. Gaist D, Jeppesen U, Andersen M, et al. Statins and risk of polyneuropathy: a casecontrol study. Neurology 2002;58:1333-7.
22. Caso G, Kelly P, McNurlan MA, et al. Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. Am J Cardiol 2007;99:1409-12.
23. Oh SJ, Dhall R, Young A, et al. Statins may aggravate myasthenia gravis. Muscle Nerve 2008;38:1101-7.
24. Danon MJ, Carpenter S. Myopathy with thick filament loss following prolonged paralysis with vacuronium during steroid treatment. Muscle Nerve 1991;14:1131.
25. Massa R, Carpenter S, Holland P, et al. Loss and renewal of thick myofilaments in glucocorticoid-treated rat soleus after denervation and reinnervation. Muscle Nerve 1992;15:1290-8.
26. Dalakas MC, Illa I, Pezeshkpour GH, et al. Mitochondrial myopathy caused by longterm zidovudine therapy. New Engl J Med 1990;322:1098-1105.
27. Dalakas MC. Peripheral neuropathy and antiretroviral drugs. J Peripher Nerv Syst 2001;6:14-20.
28. Miller KD, Cameron M, Wood LV, et al. Lactic acidosis, hepatic steatosis and mitochondrial myopathy associated with the use of stavudine (d4T). Ann Intern Med 2000;133:192-6.
29. Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med 1995;1:417.
30. Dalakas MC, Karpati G. The inflammatory myopathies. In: Karpati G, Hilton-Jones, Griggs RC, eds. Disorders of voluntary muscle. 7th edn. Cambridge: Cambridge University Press, 2001:636-59.
31. Hertzmann M, Reba RC, Kotlyarov EV. Single photon emission computed tomography in phencyclidine and related drug abuse. Am J Psychiatry 1990;147:255-6.
32. Illa I, Dinsmore S, Dalakas MC. Immune-mediated mechanisms and immune activation of fibroblasts in the pathogenesis of eosinophilia-myalgia syndrome induced by L-tryptophan. Hum Pathol 1993;24:702.
33. Gherardi RK, Coquet M, Cherin P, et al. Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminum hydroxide in muscle. Brain 2001;124:1821-31.
34. Higuchi I, Izumo S, Kuriyama M, et al. Germanium myopathy: clinical and experimental pathological studies. Acta Neuropathol (Berl) 1989;79:300-4.
35. Halbig L, Gutmann L, Goebel HH, et al. Ultrastructural pathology in emetine-induced myopathy. Acta Neuropathol (Berl) 1988;75:577-82.
36. O'Connor G, McMahon G. Complications of heroin abuse. Eur J Emerg Med 2008;15:104-6.
37. Urbano-Marquez A, Estruch R, Navarro-Lopez F, et al. The effects of alcoholism on skeletal and cardiac muscle. New Engl J Med 1989;320:409-15.
38. Melli G, Chaudhry V, Cornblath DR. Rhabdomyolysis: an evaluation of 475 hospitalized patients. Medicine (Baltimore) 2005;84:377-85.
39. Boot E, de Haan L. Massive increase in serum creatine kinase during olanzapine and quetiapine treatment, not during treatment with clozapine. Psychopharmacology (Berl) 2000;150:347-8.
40. Yuasa K, Yoshimura M, Urasawa N, et al. Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products. Gene Ther 2007;14:1249-60.